secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K/A
Filed at:   2021-08-05T23:59:59+00:00
Accession:  0000950170-21-000831
Event type: m_and_a
Sentiment:  negative
Materiality: 0.75
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics merger with Trigr completed; Trigr had $99k cash, $15.8M deficit
--------------------------------------------------------------------------------

- Trigr audited 2020: cash $99k, total liabilities $2.57M, net loss $2.11M, accumulated deficit $15.8M; going concern doubt.
- Trigr unaudited Q1 2021: cash $4.3M, net income $5.6M from $7M licensing revenue to Elpiscience.
- Merger consideration: 10.27M Compass shares at $4.90/share (~$50.3M) plus up to $9M earnout.
- Trigr lead asset CTX-009 licensed to Elpiscience for Greater China; $7M upfront, up to $110M milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000095017021000831/0000950170-21-000831-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000095017021000831/cmpx-20210625.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-000831

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer